Narcolepsy drug delay fails to dampen enthusiasm at Axsome portfolio

15 June 2023

Eagle-eyed investors might have noticed an omission from a corporate presentation by Axsome Therapeutics (Nasdaq: AXSM), but it does not appear to have damaged optimism generated by the publication.

The presentation, which featured in a filing to the US Securities and Exchange Commission on Tuesday, referenced the development of AXS-12 (reboxetine) as a treatment of a disorder characterized by excessive daytime sleepiness and cataplexy that has limited treatment options.

AXS-12 is in a Phase III trial, completion of which is expected in the third quarter of this year. Axsome did not mention, however, a date for a top-line readout of the study. This was previously stated as being this autumn.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK